5 The prevalence of MPN is commonly observed among individuals aged 50–70, primarily affecting the middle-aged and elderly population, with a notable trend toward extended patient survival. 6 The elucidation of the mechanism underlying MPN has facilitated the development of novel therapeutic agents, thereby enhancing the overall prognosis for patients with MPN. 4 The reduction in primary tumor progression results in an extended life expectancy and an elevation in various nonprimary tumor-related mortality, with a particular emphasis on CVDs.
← all excerpts
Long-term risks of cardiovascular-specific mortality among myeloproliferative neoplasms patients.
1
—
—